课题基金 / 基金详情

IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS

IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS
伊班膦酸钠治疗骨质疏松症 3 年
批准号：
6291200
负责人：
C. CONRAD JOHNSTON
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6291200
关键词：
bone density bone fracture clinical research diphosphonate drug adverse effect drug screening /evaluation female human subject human therapy evaluation intravenous administration longitudinal animal study osteoporosis placebos postmenopause skeletal disorder chemotherapy vertebrae women's health

项目摘要

项目成果

C. CONRAD JOHNSTON的其他基金

相似基金

相关文献

中文摘要
翻译
这项为期三年的III期研究的目的是通过评价间歇性静脉治疗的有效性和安全性，以新发椎骨骨折的发生率为主要终点，研究伊班膦酸盐在绝经后骨质疏松症长期治疗中的疗效。 具体目的是：确定伊班膦酸盐是否能预防绝经后骨质疏松症妇女的骨折和骨丢失。确定与伊班膦酸盐静脉给药相关的副作用类型确定治疗后血液中伊班膦酸盐的量并估计药物在血液中停留的时间
英文摘要
The purpose of this three year phase III study is to investigate the therapeutic effect of ibandronate in the long-term treatment of postmenopausal osteoporosis by evaluating the efficacy and safety of intermittent intravenous treatment using the incidence of new vertebral fractures as the primary endpoint. The specific objectives are: To determine whether Ibandronate prevents fractures and bone loss in women with established postmenopausal osteoporosis. To determine the type of side effects associated with the i.v. administration of Ibandronate To determine the amount of Ibandronate in the blood following treatment and to estimate how long the drug stays in the blood
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ROLE OF SEX STEROIDS IN AGE-RELATED BONE LOSS
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
海外基金